CROs Counting On Biotech Stock Rise, Phase IV Trials To Drive New Business
Executive Summary
Recently enriched biotechnology companies will help the contract research organization market recover from its slump in the coming year, PPD CEO Fred Eshelman, MD, told analysts during an April 20 conference call.